The new multicenter, retrospective cohort study included 174 patients with ACHD receiving SGLT2 inhibitors, mean age 48.7 years. Most had quite complex disease; 51.1% had severe congenital heart ...

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

A recent review in Current Diabetes Reports delves into the utility of sodium-glucose co-transporter-2 (SGLT2) inhibitors for patients with heart failure currently on other medications.

Marx, N. and Müller-Wieland, D. (2023) "SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world", European Heart Journal. doi : 10. ...

Given the speed at which SGLT2 inhibitors work, with heart failure benefits accruing within just a few weeks in randomized trials, Kosiborod said lost time is an important consequence of each ...

Findings from a recent systematic review and meta-analysis support the initiation of SGLT2 inhibitors for inpatients hospitalized with acute heart failure. 18 Included in the meta-analysis were ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

After 1 year of treatment, SGLT2 inhibitors were associated with a 32% lower risk for hospitalization due to heart failure, regardless of type 2 diabetes status, according to a new study in Annals ...

In the present study, SGLT2-inhibitor users consistently had a lower risk for lupus nephritis, dialysis, heart failure and all-cause mortality vs. nonusers. We look forward to further developments ...